Journal Article

Development, Acceptance, and Use of Immunologic Correlates of Protection in Monitoring the Effectiveness of Combination Vaccines

Kathryn M. Edwards

in Clinical Infectious Diseases

Published on behalf of Infectious Diseases Society of America

Volume 33, issue Supplement_4, pages S274-S277
Published in print December 2001 | ISSN: 1058-4838
Published online December 2001 | e-ISSN: 1537-6591 | DOI: http://dx.doi.org/10.1086/322562
Development, Acceptance, and Use of Immunologic Correlates of Protection in Monitoring the Effectiveness of Combination Vaccines

More Like This

Show all results sharing these subjects:

  • Infectious Diseases
  • Immunology
  • Public Health and Epidemiology
  • Microbiology

GO

Show Summary Details

Preview

The establishment of immunologic correlates of protection for all vaccine antigens is a worthwhile goal. It allows new vaccines to be licensed on the basis of attainment of defined immunologic benchmarks, without the need for large-scale efficacy trials for each new product. This is particularly important for the evaluation of new combination products. Efficacy trials of each new mixture would be unethical because routinely recommended vaccines would be denied children in the control group. The establishment of immunologic correlates of protection should be a defined goal of every efficacy trial. Additional ways to evaluate the immune responses—such as cell-mediated immunity, mucosal immunity, memory responses, and antibody avidity—should also be studied. Finally, ongoing surveillance efforts are also needed, to monitor the impact of new and combined vaccines on disease rates.

Journal Article.  2586 words.  Illustrated.

Subjects: Infectious Diseases ; Immunology ; Public Health and Epidemiology ; Microbiology

Full text: subscription required

How to subscribe Recommend to my Librarian

Users without a subscription are not able to see the full content. Please, subscribe or login to access all content.